GENEVA–(BUSINESS WIRE)–Alcon Announces Executive Committee Changes
Author: Business Wire
Alcon Announces Executive Committee Changes
GENEVA–(BUSINESS WIRE)–Alcon Announces Executive Committee Changes
Samenvatting: Teva en Bioeq kondigen commerciële samenwerking aan voor Biosimilar
TEL AVIV, Israël & ZURRICH–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE: en TASE: TEVA) en Bioeq AG (“Bioeq”) hebben vandaag aangekondigd dat ze een strategisch partnerschap zijn aangegaan voor de exclusieve commercialisering van Bioeq’s…
Resumen: Teva y Bioeq anuncian una asociación comercial para un biosimilar
TEL AVIV, Israel y ZURICH–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE: y TASE: TEVA) y Bioeq AG (“Bioeq”) han anunciado hoy que han firmado una asociación estratégica para la comercialización exclusiva de FYB201 de Bioeq, un candidato a…
Teva et Bioeq annoncent un partenariat commercial dans le domaine des biosimilaires
TEL AVIV, Israël, et ZURICH–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA) et Bioeq AG (“Bioeq”) ont annoncé aujourd’hui avoir conclu un partenariat stratégique pour la commercialisation exclusive du FYB201 de Bioeq, un can…
Riassunto: Enspryng (Satralizumab) di Chugai approvato dalla Commissione europea quale primo trattamento sottocutaneo a domicilio per il disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha annunciato oggi che a Roche è stata concessa l’Autorizzazione all’immissione in commercio della Commissione europea per l’anticorpo monoclonale umanizzato anti-recettore IL-6 lega…
Pas de répit pour les yeux fatigués : Une pandémie d'utilisation accrue de la vision de près chez les enfants canadiens(1) – Sondage CooperVision
TORONTO–(BUSINESS WIRE)–Alors que la perspective du retour à la normale semble moins lointaine, un nouveau sondage réalisé par CooperVision Canada et par Maru/Blue1 suggère que la pandémie pourrait avoir généré des habitudes de vision de près, ce qui…
No Rest for the Weary Eyes: A Pandemic of Increased Near-Vision Use for Canadian Children(1) – CooperVision Survey
TORONTO–(BUSINESS WIRE)–While the horizon of a return to normal seems less distant, a new survey by CooperVision Canada and Maru/Blue1 suggests that the pandemic may have generated near-vision habits, which according to experts could have an impact o…
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
DUBLIN–(BUSINESS WIRE)–Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Teva and Bioeq Announce Commercial Partnership for Biosimilar
TEL AVIV, Israel & ZURICH–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG (“Bioeq”) today announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq’s FYB201, a b…
Resumen: Enspryng (satralizumab) de Chugai, aprobado por la Comisión Europea como el primer tratamiento subcutáneo de administración domiciliaria contra la neuromielitis óptica (NMO)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado hoy que Roche ha obtenido la autorización de comercialización de la Comisión Europea para el anticuerpo monoclonal humanizado contra el receptor de IL-6 de unión dependi…
Samenvatting: Chugai’s Enspryng (Satralizumab) goedgekeurd door de Europese Commissie als eerste subcutane behandeling thuis voor neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft vandaag aangekondigd dat Roche een vergunning voor het in de handel brengen heeft gekregen van de Europese Commissie voor het pH-afhankelijke bindende gehumaniseerde anti-IL-6-…
Enspryng (Satralizumab) de Chugai approuvé par la Commission européenne en tant que premier traitement sous-cutané à domicile pour le trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé aujourd’hui que Roche avait obtenu l’autorisation de mise sur le marché de la Commission européenne pour l’anticorps monoclonal humanisé anti-récepteur de l’IL-6 à liaison…
Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche has been granted Marketing Authorization from the European Commission for the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Enspryn…
Second Sight Medical Products Announces Closing of Public Offering
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individu…
OcuTerra Appoints David J. Tanzer, MD, as Chief Medical Officer
BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics appoints David J. Tanzer, MD, as Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs
UM School of Medicine Receives Award for Research on Aging and Cognitive Function
MIAMI–(BUSINESS WIRE)–The Dr. M. Lee Pearce Foundation announces funding to UM’s School of Medicine in support of its research on aging and cognitive function.
Santen Receives FDA Approval for Verkazia™ (Cyclosporine Ophthalmic Emulsion) 0.1% for the Treatment of Vernal Keratoconjunctivitis in Children and Adults
EMERYVILLE, Calif.–(BUSINESS WIRE)–The U.S. FDA has approved Santen’s Verkazia™ (cyclosporine ophthalmic emulsion) 0.1% eye drops for the treatment of VKC in children and adults.
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Pr…
Zenni Surpasses 40 Million Pairs of Glasses Sold Across 18 Years of Uncharted Growth
NOVATO, Calif.–(BUSINESS WIRE)–Zenni, the online eyewear retail leader, announced today it has surpassed another industry milestone, selling more than 40 million pairs of frames since its launch in 2003. In 2020 alone, the direct to consumer retail p…